Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.
Barbara Katharina GeistHelmut BrathLucia ZisserJosef YuBarbara FuegerLukas NicsEva Maria PatronasAlexandra Kautzky-WillerMarcus HackerSazan RasulPublished in: European journal of nuclear medicine and molecular imaging (2023)
Using Me4FDG-PET, we demonstrated for the first time renal SGLT2-related excretion before and after short-term SGLT2i treatment. In contrary to other clinical parameters, SGLT2-related excretion before treatment was a robust predictor of long-term HbA1c response in patients with type 2 diabetes, suggesting that therapy effectiveness is only dependent of endogenous SGLT2 processes.